Alternatives to traditional care for ADHD, including novel digital therapeutics, have shown promise to remediate cognitive deficits associated with this disorder and may address barriers to standard therapies, such as pharmacological interventions and behavioral therapy.

Digital therapeutics for ADHD may address the limitations of pharmacotherapy treatment with improved access, minimal side-effects and low potential for abuse.

EndeavorRx – Non-drug treatment for ADHD in children

Food and Drug Administration (FDA) permitted marketing of the first game-based digital therapeutic device to improve attention function in children with attention deficit hyperactivity disorder (ADHD). The prescription-only game-based device, called EndeavorRx, is indicated for pediatric patients ages 8 to12 years old with primarily inattentive or combined-type ADHD who have demonstrated an attention issue.

EndeavorRx is indicated to improve attention function as measured by computer-based testing and is the first digital therapeutic intended to improve symptoms associated with ADHD, as well as the first game-based therapeutic granted marketing authorization by the FDA for any type of condition.

The device is intended for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder.

The video game-like interface was used 25 minutes a day, 5 days a week, for 4 weeks and was found to improve attentional functioning significantly as reported by both patients and parents.

After one month of use, roughly half of parents reported clinically meaningful improvement in their child’s daily impairments. “Moreover, this increased to 68% after a second month of treatment. Following a month of treatment, improvements in ADHD impairments were maintained for up to 1 month,” according to the Akili news release.2 A small percentage of participants experienced minor adverse effects that included frustration, headache, dizziness, emotional reaction, nausea, or aggression.

More information about EndeavorRx @ https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-game-based-digital-therapeutic-improve-attention-function-children-adhd , https://www.psychiatrictimes.com/view/video-game-will-see-you-now , https://my.akili.care/akiliassist/ and https://www.endeavorrx.com/ .

Leave a Reply